Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biotherapeutics

Kerry Chester's Biography

Kerry Chester, Professor, University College London

Professor Kerry Chester leads the Recombinant Antibody Therapeutics Group at the UCL Cancer Institute ( Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets. The work is largely translational and aimed at developing new agents for clinical use. To facilitate this, her group has established an academic GMP facility to make clinical grade recombinant proteins for use in First-in-Man and Phase I/II cancer trials. Kerry’s current research includes developing antibodies as cancer imaging agents, as therapeutic fusion proteins and to target novel nanomedicines.

Kerry Chester Image

Exploring the Potential of Antibody-Targeted Nanoparticles for Cancer Treatment

Thursday, 28 June 2012 at 10:00

Add to Calendar ▼2012-06-28 10:00:002012-06-28 11:00:00Europe/LondonExploring the Potential of Antibody-Targeted Nanoparticles for Cancer

Antibody-targeted superparamagnetic iron oxide nanoparticles (SPION) have potential to provide selective tumour imaging followed by potent localized hyperthermic therapy upon application of an alternating magnetic field. The feasibility and translational challenges of these new nanomedicines will be discussed.

Add to Calendar ▼2012-06-27 00:00:002012-06-28 00:00:00Europe/